Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease

With a positive regulatory environment, “promising science,” according to McKee, an experienced team and a $51M Series A round of investment led by Arch Venture Partners and UCB Ventures, the 12-person Walden Biosciences hopes to enter the trial and clinical phases soon.(© Bill Horsman Photography)

In the U.S., about 37 million people live with kidney disease, which is more than 1 in 7 American adults. But Blaine McKee, the CEO of the newly unveiled Cambridge, MA, startup Walden Biosciences, hopes to change that.

McKee and his team founded the company to reverse the progression of kidney disease for a “massively underserved” patient population. And with a positive regulatory environment, “promising science,” an experienced team and $51 million in series A cash, the 12-person company hopes to hit the clinic soon.

Blaine McKee, CEO of Walden BioSciences, hopes to reverse kidney disease for a "massively underserved" patient population. 

Walden is taking a two-pronged approach: antibodies and small molecules. Its first approach targets soluble urokinase plasminogen activating receptor (suPAR), a protein that signals kidney disease, with the goal of reducing inflammation and boosting kidney function. "There are very strong disease associations between the levels of suPAR and acute kidney injury, chronic kidney disease,” Walden's chief scientific officer, Alex Duncan, said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

The second is designed to preserve podocytes, or kidney cells that aid in filtration, by activating an enzyme called dynamin, which maintains the structure of the kidneys' filtration apparatus.

“We've taken a bottom-up reductionist approach to really try and understand the role of individual components, but also a top-down holistic approach,” Duncan said. “The situation really with the kidneys is this structure is absolutely unique as an organ and it has both the mechanical as well as the biochemical functions.”

Chief scientific officer Alex Duncan advises taking both a reductionist and holistic approach to reversing kidney disease. 

The company is focused largely on kidney disease “because that's where we see the opportunity and where we see patients that actually have no real options, or at least in end-stage renal disease, it's dialysis or transplantation,” Duncan said, adding that the disease also carries a high risk of mortality.

RELATED: Sentien heads to clinic with blood conditioning device for renal failure.

The COVID-19 pandemic has shone a spotlight on the kidneys, too: More than 20% of intensive care unit patients with COVID-19 have lost kidney function, according to the National Kidney Foundation.

And in that regard, Walden may be uniquely positioned to help. “People with higher levels of suPAR actually have a worse prognosis for COVID ... so that's one area that we may look at,” Duncan said.

For now, though, Walden will use the funding—which came from Arch and UCB Ventures—to get both programs into the clinic and add a few new members to the team.

“Our objective is to totally change the face of renal diseases. Historically, they would potentially slow the progression, manage hypertension, glucose levels. We’re quite ambitious here. We're looking to completely transform the treatment—not just slow it, but reverse it,” McKee said. And while the funding is an important milestone, “we think it’s just the beginning.”

Read more on

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.